244 related articles for article (PubMed ID: 32601077)
1. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
Martín-Broto J; Moura DS; Van Tine BA
Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
[TBL] [Abstract][Full Text] [Related]
2. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
3. New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas.
Seong G; D'Angelo SP
Front Oncol; 2023; 13():1150765. PubMed ID: 37007160
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
Wood GE; Meyer C; Petitprez F; D'Angelo SP
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
[TBL] [Abstract][Full Text] [Related]
6. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
Wisdom AJ; Mowery YM; Hong CS; Himes JE; Nabet BY; Qin X; Zhang D; Chen L; Fradin H; Patel R; Bassil AM; Muise ES; King DA; Xu ES; Carpenter DJ; Kent CL; Smythe KS; Williams NT; Luo L; Ma Y; Alizadeh AA; Owzar K; Diehn M; Bradley T; Kirsch DG
Nat Commun; 2020 Dec; 11(1):6410. PubMed ID: 33335088
[TBL] [Abstract][Full Text] [Related]
7. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
8. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy.
Subramanian A; Nemat-Gorgani N; Ellis-Caleo TJ; van IJzendoorn DGP; Sears TJ; Somani A; Luca BA; Zhou MY; Bradic M; Torres IA; Oladipo E; New C; Kenney DE; Avedian RS; Steffner RJ; Binkley MS; Mohler DG; Tap WD; D'Angelo SP; van de Rijn M; Ganjoo KN; Bui NQ; Charville GW; Newman AM; Moding EJ
Nat Cancer; 2024 Apr; 5(4):642-658. PubMed ID: 38429415
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Immunotherapy for Retroperitoneal Sarcoma.
Gingrich AA; Nassif EF; Roland CL; Keung EZ
Curr Oncol; 2023 Feb; 30(2):2144-2158. PubMed ID: 36826126
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of sarcomas with modified T cells.
Mahalingam P; Julve M; Huang P; Furness AJS; Pollack SM; Jones RL
Curr Opin Oncol; 2022 Jul; 34(4):362-370. PubMed ID: 35837706
[TBL] [Abstract][Full Text] [Related]
12. Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
Kerrison WGJ; Lee ATJ; Thway K; Jones RL; Huang PH
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327375
[TBL] [Abstract][Full Text] [Related]
13. The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.
Crombé A; Roulleau-Dugage M; Italiano A
Cancer Commun (Lond); 2022 Dec; 42(12):1288-1313. PubMed ID: 36260064
[TBL] [Abstract][Full Text] [Related]
14. Immune Therapy for Sarcomas.
Anderson PM
Adv Exp Med Biol; 2017; 995():127-140. PubMed ID: 28321815
[TBL] [Abstract][Full Text] [Related]
15. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
[TBL] [Abstract][Full Text] [Related]
16. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing for the management of sarcomas with no known driver mutations.
Vyse S; Thway K; Huang PH; Jones RL
Curr Opin Oncol; 2021 Jul; 33(4):315-322. PubMed ID: 33927108
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor.
Baldi GG; Gronchi A; Tazzari M; Stacchiotti S
Expert Rev Anticancer Ther; 2022 May; 22(5):491-503. PubMed ID: 35412415
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.
Fazel M; Dufresne A; Vanacker H; Waissi W; Blay JY; Brahmi M
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980528
[TBL] [Abstract][Full Text] [Related]
20. Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy.
de Nigris F; Meo C; Palinski W
Cells; 2023 Sep; 12(17):. PubMed ID: 37681936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
